nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—DCK—Purine salvage—APRT—nephrolithiasis	0.0836	0.152	CbGpPWpGaD
Fludarabine—DCK—Purine metabolism—APRT—nephrolithiasis	0.0397	0.0722	CbGpPWpGaD
Fludarabine—RRM1—Nucleotide metabolism—APRT—nephrolithiasis	0.0259	0.0472	CbGpPWpGaD
Fludarabine—Adenosine monophosphate—APRT—nephrolithiasis	0.0258	1	CrCbGaD
Fludarabine—DCK—Nucleotide metabolism—APRT—nephrolithiasis	0.0199	0.0363	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.0188	0.0343	CbGpPWpGaD
Fludarabine—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.0179	0.046	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0172	0.0313	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0172	0.0313	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.014	0.0255	CbGpPWpGaD
Fludarabine—Numbness—Hydrochlorothiazide—nephrolithiasis	0.0138	0.0352	CcSEcCtD
Fludarabine—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.0132	0.0337	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.013	0.0237	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.013	0.0237	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0128	0.0234	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0128	0.0234	CbGpPWpGaD
Fludarabine—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0315	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0121	0.0221	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0121	0.0221	CbGpPWpGaD
Fludarabine—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.0116	0.0297	CcSEcCtD
Fludarabine—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0287	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.0108	0.0197	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.0107	0.0195	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.0107	0.0195	CbGpPWpGaD
Fludarabine—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0267	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00973	0.0177	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00973	0.0177	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00956	0.0174	CbGpPWpGaD
Fludarabine—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00956	0.0245	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00904	0.0165	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00904	0.0165	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00875	0.0159	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00875	0.0159	CbGpPWpGaD
Fludarabine—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.00873	0.0224	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00828	0.0212	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00806	0.0147	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.008	0.0146	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.008	0.0146	CbGpPWpGaD
Fludarabine—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00764	0.0196	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00745	0.0191	CcSEcCtD
Fludarabine—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00715	0.0183	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00713	0.013	CbGpPWpGaD
Fludarabine—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00697	0.0178	CcSEcCtD
Fludarabine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00669	0.0171	CcSEcCtD
Fludarabine—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00669	0.0171	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00665	0.017	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00663	0.0121	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00663	0.0121	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00652	0.0119	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00652	0.0119	CbGpPWpGaD
Fludarabine—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00645	0.0165	CcSEcCtD
Fludarabine—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00641	0.0164	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00632	0.0162	CcSEcCtD
Fludarabine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00629	0.0161	CcSEcCtD
Fludarabine—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00627	0.0161	CcSEcCtD
Fludarabine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00625	0.016	CcSEcCtD
Fludarabine—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00625	0.016	CcSEcCtD
Fludarabine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.0062	0.0159	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00616	0.0112	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00616	0.0112	CbGpPWpGaD
Fludarabine—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00608	0.0156	CcSEcCtD
Fludarabine—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00602	0.0154	CcSEcCtD
Fludarabine—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00598	0.0153	CcSEcCtD
Fludarabine—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.0057	0.0146	CcSEcCtD
Fludarabine—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00568	0.0146	CcSEcCtD
Fludarabine—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00552	0.0141	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00549	0.01	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00549	0.01	CbGpPWpGaD
Fludarabine—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00541	0.0139	CcSEcCtD
Fludarabine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00511	0.0131	CcSEcCtD
Fludarabine—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00506	0.013	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00494	0.009	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00494	0.009	CbGpPWpGaD
Fludarabine—RRM1—nephron tubule—nephrolithiasis	0.00477	0.138	CbGeAlD
Fludarabine—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00462	0.0118	CcSEcCtD
Fludarabine—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00461	0.0118	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00459	0.00836	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00459	0.00836	CbGpPWpGaD
Fludarabine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00458	0.0117	CcSEcCtD
Fludarabine—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00449	0.0115	CcSEcCtD
Fludarabine—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00446	0.0114	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00439	0.00799	CbGpPWpGaD
Fludarabine—Cough—Hydrochlorothiazide—nephrolithiasis	0.00435	0.0111	CcSEcCtD
Fludarabine—RRM1—renal system—nephrolithiasis	0.00434	0.126	CbGeAlD
Fludarabine—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00424	0.0109	CcSEcCtD
Fludarabine—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00424	0.0109	CcSEcCtD
Fludarabine—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00419	0.0107	CcSEcCtD
Fludarabine—RRM1—kidney—nephrolithiasis	0.00419	0.121	CbGeAlD
Fludarabine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.0041	0.0105	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00409	0.00746	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00409	0.00746	CbGpPWpGaD
Fludarabine—RRM1—cortex of kidney—nephrolithiasis	0.00408	0.118	CbGeAlD
Fludarabine—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00407	0.0104	CcSEcCtD
Fludarabine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00407	0.0104	CcSEcCtD
Fludarabine—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00398	0.0102	CcSEcCtD
Fludarabine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00393	0.0101	CcSEcCtD
Fludarabine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00388	0.00993	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00371	0.00949	CcSEcCtD
Fludarabine—DCK—nephron tubule—nephrolithiasis	0.00371	0.107	CbGeAlD
Fludarabine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00365	0.00936	CcSEcCtD
Fludarabine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00363	0.00929	CcSEcCtD
Fludarabine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00358	0.00917	CcSEcCtD
Fludarabine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00354	0.00906	CcSEcCtD
Fludarabine—SLC29A1—renal system—nephrolithiasis	0.00353	0.102	CbGeAlD
Fludarabine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00351	0.00898	CcSEcCtD
Fludarabine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00348	0.00891	CcSEcCtD
Fludarabine—Pain—Hydrochlorothiazide—nephrolithiasis	0.00348	0.00891	CcSEcCtD
Fludarabine—SLC29A1—kidney—nephrolithiasis	0.00341	0.0988	CbGeAlD
Fludarabine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00335	0.00859	CcSEcCtD
Fludarabine—SLC29A1—cortex of kidney—nephrolithiasis	0.00332	0.0962	CbGeAlD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00327	0.00596	CbGpPWpGaD
Fludarabine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00322	0.00824	CcSEcCtD
Fludarabine—DCK—cortex of kidney—nephrolithiasis	0.00317	0.0919	CbGeAlD
Fludarabine—RRM1—Metabolism—GRHPR—nephrolithiasis	0.0031	0.00565	CbGpPWpGaD
Fludarabine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.003	0.00768	CcSEcCtD
Fludarabine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00292	0.00748	CcSEcCtD
Fludarabine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00288	0.00737	CcSEcCtD
Fludarabine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00278	0.00713	CcSEcCtD
Fludarabine—RRM1—Metabolism—AGXT—nephrolithiasis	0.00277	0.00504	CbGpPWpGaD
Fludarabine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00259	0.00662	CcSEcCtD
Fludarabine—Rash—Hydrochlorothiazide—nephrolithiasis	0.00256	0.00657	CcSEcCtD
Fludarabine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00256	0.00656	CcSEcCtD
Fludarabine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00653	CcSEcCtD
Fludarabine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00242	0.00619	CcSEcCtD
Fludarabine—DCK—Metabolism—GRHPR—nephrolithiasis	0.00239	0.00435	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—SLC26A1—nephrolithiasis	0.00235	0.00428	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—APRT—nephrolithiasis	0.00235	0.00428	CbGpPWpGaD
Fludarabine—DCK—Metabolism—AGXT—nephrolithiasis	0.00213	0.00388	CbGpPWpGaD
Fludarabine—DCK—Metabolism—APRT—nephrolithiasis	0.00181	0.0033	CbGpPWpGaD
Fludarabine—DCK—Metabolism—SLC26A1—nephrolithiasis	0.00181	0.0033	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—AQP1—nephrolithiasis	0.00168	0.00305	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CHRM3—nephrolithiasis	0.00152	0.00276	CbGpPWpGaD
Fludarabine—DCK—Metabolism—AQP1—nephrolithiasis	0.00129	0.00235	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CHRM3—nephrolithiasis	0.00117	0.00212	CbGpPWpGaD
